Navigation Links
China's Type 2 Diabetes Drug Market Will More than Triple by 2012
Date:5/28/2008

New Entries to China Drug Market to Garner More Than $270 Million in

Combined Sales, According to a New Report by Decision Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes drug market will more than triple by 2012. According to the new Emerging Markets report entitled Type 2 Diabetes in China, this growth will be fueled by increased access to health insurance, greater patient spending power and more aggressive treatment practice, leading to increased usage of newer agents such as the insulin analogues. Additionally, the number of prevalent cases of type 2 diabetes in China is among the highest in the world -- 62.5 million cases in 2007 -- a number that rivals that of the United States, Europe and Japan combined (48.5 million cases). The high prevalence rate in China reflects an aging population and urbanization-associated risk factors, such as diet and lack of physical activities.

"The Chinese government and medical associations are promoting guidelines published by the American Diabetes Association, the World Health Organization and the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst at Decision Resources. "All guidelines advocate earlier and more-aggressive interventions in type 2 diabetes patients. We forecast that the patient population treated with polypharmacy will nearly double between 2007 and 2012."

The report also finds that three new type 2 diabetes agents with novel mechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis's Galvus -- are expected to launch in China by 2012. The combined sales of these three agents will surpass $270 million by 2012. However, the high cost of many antidiabetic therapies, particularly Western-branded drugs, is a major barrier to effective management of type 2 diabetes in China. Patient ability to pay for medications influences physician prescribing habits, particularly prescription of newer drugs such as the peroxisome proliferator-activated receptor (PPAR)-gamma agonists and the insulin analogues, which are not reimbursed or are only partially reimbursed in some provinces.

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess the commercial opportunity for Western brands in

key pharmaceutical markets of China -- Beijing, Shanghai,

Guangzhou -- and in the high-growth second-tier markets of Tianjin,

Wuhan, Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese five-year market forecast at

the drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New insights in diagnosing diabetes may help the millions who are undiagnosed
3. Rhinestone Cure Sets the Glitz to Benefit Diabetes at Hotel Indigo
4. New Antioxidant Drug Shows Promise Against Diabetes
5. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
6. Anti-rejection drug may increase risk of diabetes after kidney transplant
7. Study: Doctors not always sure when to treat BP in people with diabetes
8. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
9. Seattle Laces Up To Beat the Bridge and Diabetes
10. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
11. American Diabetes Wholesale Launches Affiliate Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider of ... other difficult to transfect cells, announces its launch of the PluriQ™ G9™ Gene ... System is a complete system for culturing and transfecting human pluripotent stem ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: